Shopping Cart 0
Cart Subtotal
USD 0

Kazia Therapeutics Ltd (KZA) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Kazia Therapeutics Ltd (KZA)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (ATM) and super-benzopyrans (SBP). ATM drugs that target the cancer cell cytoskeleton are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. SBP drugs that target cancer stem cells are being developed for the treatment of ovarian cancer and glioblastoma. The PI3K inhibitor functions by inhibiting an important signaling pathway which is critical to the development of certain kinds of tumors. The company's product pipeline includes PI3K GDC-0084; Cantrixil (TRX-E-002-1). Kazia is headquartered in New South Wales, Australia.

Kazia Therapeutics Ltd Key Recent Developments

Feb 19,2018: Kazia Change Of Registered Office And Business Address

Aug 29,2017: Novogen Annual Report And Full-year Financial Results

Aug 14,2017: Novogen: Board Review Of Business Operations And Governance

Jun 08,2017: Novogen Streamlines Board and Costs

Mar 10,2017: Novogen Announces Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Kazia Therapeutics Ltd-Key Facts 5

Kazia Therapeutics Ltd-Key Employees 6

Kazia Therapeutics Ltd-Key Employee Biographies 7

Kazia Therapeutics Ltd-Major Products and Services 8

Kazia Therapeutics Ltd-History 9

Kazia Therapeutics Ltd-Locations And Subsidiaries 12

Head Office 12

Other Locations & Subsidiaries 12

Section 2-Company Analysis 13

Company Overview 13

Kazia Therapeutics Ltd-Business Description 14

Kazia Therapeutics Ltd-Corporate Strategy 15

Kazia Therapeutics Ltd-SWOT Analysis 16

SWOT Analysis-Overview 16

Kazia Therapeutics Ltd-Strengths 16

Kazia Therapeutics Ltd-Weaknesses 17

Kazia Therapeutics Ltd-Opportunities 18

Kazia Therapeutics Ltd-Threats 19

Kazia Therapeutics Ltd-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's Lifesciences Financial Deals and Alliances 27

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

Kazia Therapeutics Ltd, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

Feb 19, 2018: Kazia Change Of Registered Office And Business Address 30

Aug 29, 2017: Novogen Annual Report And Full-year Financial Results 31

Aug 14, 2017: Novogen: Board Review Of Business Operations And Governance 33

Jun 08, 2017: Novogen Streamlines Board and Costs 34

Mar 10, 2017: Novogen Announces Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure 35

Mar 10, 2017: Novogen: Transformation To A Clinical Stage Organisation Leads To Changes In Management Structure 36

Section 6-Appendix 37

Methodology 37

Ratio Definitions 37

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Kazia Therapeutics Ltd, Performance Chart (2014-2018) 24

Kazia Therapeutics Ltd, Ratio Charts 26

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28


List Of Table

List of Tables

Kazia Therapeutics Ltd, Key Facts 5

Kazia Therapeutics Ltd, Key Employees 6

Kazia Therapeutics Ltd, Key Employee Biographies 7

Kazia Therapeutics Ltd, Major Products and Services 8

Kazia Therapeutics Ltd, History 9

Kazia Therapeutics Ltd, Subsidiaries 12

Kazia Therapeutics Ltd, Key Competitors 20

Kazia Therapeutics Ltd, Ratios based on current share price 21

Kazia Therapeutics Ltd, Annual Ratios 22

Kazia Therapeutics Ltd, Annual Ratios (Cont...1) 23

Kazia Therapeutics Ltd, Interim Ratios 25

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

Kazia Therapeutics Ltd, Recent Deals Summary 29

Currency Codes 37

Capital Market Ratios 37

Equity Ratios 38

Profitability Ratios 38

Cost Ratios 39

Liquidity Ratios 39

Leverage Ratios 40

Efficiency Ratios 40

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Kazia Therapeutics Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Viralytics Ltd

Teva Pharmaceutical Industries Ltd

Prescient Therapeutics Ltd

Life Technologies Corp

Gilead Sciences Ltd

Genentech Inc

Cancure Ltd

Biogen Inc

Amgen Inc

Kazia Therapeutics Ltd (KZA)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (ATM) and super-benzopyrans (SBP). ATM drugs that target the cancer cell cytoskeleton are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. SBP drugs that target cancer stem cells are being developed for the treatment of ovarian cancer and glioblastoma. The PI3K inhibitor functions by inhibiting an important signaling pathway which is critical to the development of certain kinds of tumors. The company's product pipeline includes PI3K GDC-0084; Cantrixil (TRX-E-002-1). Kazia is headquartered in New South Wales, Australia.

Kazia Therapeutics Ltd Key Recent Developments

Feb 19,2018: Kazia Change Of Registered Office And Business Address

Aug 29,2017: Novogen Annual Report And Full-year Financial Results

Aug 14,2017: Novogen: Board Review Of Business Operations And Governance

Jun 08,2017: Novogen Streamlines Board and Costs

Mar 10,2017: Novogen Announces Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Kazia Therapeutics Ltd-Key Facts 5

Kazia Therapeutics Ltd-Key Employees 6

Kazia Therapeutics Ltd-Key Employee Biographies 7

Kazia Therapeutics Ltd-Major Products and Services 8

Kazia Therapeutics Ltd-History 9

Kazia Therapeutics Ltd-Locations And Subsidiaries 12

Head Office 12

Other Locations & Subsidiaries 12

Section 2-Company Analysis 13

Company Overview 13

Kazia Therapeutics Ltd-Business Description 14

Kazia Therapeutics Ltd-Corporate Strategy 15

Kazia Therapeutics Ltd-SWOT Analysis 16

SWOT Analysis-Overview 16

Kazia Therapeutics Ltd-Strengths 16

Kazia Therapeutics Ltd-Weaknesses 17

Kazia Therapeutics Ltd-Opportunities 18

Kazia Therapeutics Ltd-Threats 19

Kazia Therapeutics Ltd-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's Lifesciences Financial Deals and Alliances 27

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

Kazia Therapeutics Ltd, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

Feb 19, 2018: Kazia Change Of Registered Office And Business Address 30

Aug 29, 2017: Novogen Annual Report And Full-year Financial Results 31

Aug 14, 2017: Novogen: Board Review Of Business Operations And Governance 33

Jun 08, 2017: Novogen Streamlines Board and Costs 34

Mar 10, 2017: Novogen Announces Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure 35

Mar 10, 2017: Novogen: Transformation To A Clinical Stage Organisation Leads To Changes In Management Structure 36

Section 6-Appendix 37

Methodology 37

Ratio Definitions 37

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Kazia Therapeutics Ltd, Performance Chart (2014-2018) 24

Kazia Therapeutics Ltd, Ratio Charts 26

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28


List Of Table

List of Tables

Kazia Therapeutics Ltd, Key Facts 5

Kazia Therapeutics Ltd, Key Employees 6

Kazia Therapeutics Ltd, Key Employee Biographies 7

Kazia Therapeutics Ltd, Major Products and Services 8

Kazia Therapeutics Ltd, History 9

Kazia Therapeutics Ltd, Subsidiaries 12

Kazia Therapeutics Ltd, Key Competitors 20

Kazia Therapeutics Ltd, Ratios based on current share price 21

Kazia Therapeutics Ltd, Annual Ratios 22

Kazia Therapeutics Ltd, Annual Ratios (Cont...1) 23

Kazia Therapeutics Ltd, Interim Ratios 25

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

Kazia Therapeutics Ltd, Recent Deals Summary 29

Currency Codes 37

Capital Market Ratios 37

Equity Ratios 38

Profitability Ratios 38

Cost Ratios 39

Liquidity Ratios 39

Leverage Ratios 40

Efficiency Ratios 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Kazia Therapeutics Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Viralytics Ltd

Teva Pharmaceutical Industries Ltd

Prescient Therapeutics Ltd

Life Technologies Corp

Gilead Sciences Ltd

Genentech Inc

Cancure Ltd

Biogen Inc

Amgen Inc